Atavistik Bio, Pfizer collaborate to accelerate discovery of novel precision Allosteric Therapeutics
Cambridge: Atavistik Bio, a biotechnology company has announced that it has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics to address significant unmet medical needs.
Under the terms of the collaboration, Atavistik Bio will leverage its proprietary AMPS platform to identify novel allosteric binders against two undisclosed, targets selected by Pfizer. At the completion of the research period, Pfizer will have the option to license the programs. The financial terms of the collaboration are undisclosed.
“Allostery holds the key to targeting disease-causing proteins and delivering highly selective, better tolerated, and more effective therapies. We’re excited to collaborate with Pfizer to harness the tremendous promise of allostery to advance the opportunity for therapeutic innovations for patients in need,” said Bryan Stuart, CEO of Atavistik Bio. “Our internal pipeline has been enabled by our ability to identify novel, functional allosteric binding pockets that allow us to rapidly progress novel chemical matter. We look forward to applying the efficiency and productivity of our platform to our collaboration with Pfizer as we simultaneously advance our internal pipeline of precision oncology small molecule therapies.”
Read also: USFDA nod to Pfizer Braftovi Combination Regimen for BRAF V600E-Mutant Metastatic Colorectal Cancer
Atavistik Bio’s proprietary AMPS platform is a highly integrated discovery engine that combines proprietary computational and experimental techniques to rapidly unlock functional cryptic pockets across a broad range of target classes. By leveraging insights from these novel allosteric chemical starting points, the platform enables the design of small molecules against historically challenging targets.
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics. ATV-1601, a selective allosteric inhibitor for solid tumors, is anticipated to enter the clinic in early 2025.
Read also: Pfizer Gets CDSCO Panel nod to Import Abrocitinib tablets for moderate to severe atopic dermatitis
